MNMercedes Núñez

Mercedes Núñez

*This is an algorithmically generated author record based on publicly available information.

Mercedes Núñez has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review

    by Enrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, David Vidal Sarró, Ignasi Figueras-Nart, Juan F. Silvestre Salvador, Yolanda Gilaberte, Sergio Santos Alarcón, Esther Serra-Baldrich, Monica Munera Campos, et al.

    Introduction Baricitinib has shown positive results in clinical trials both from efficacy and safety outcomes; however, there is still a need to further understand its use in routine practice in Spain. Methods This observational study aimed to describe treatment patterns, persistence, and effectiveness of baricitinib among adult patients with atopic dermatitis (AD) in Spain. A retrospective chart review was carried out in 13 hospitals across Spain. Effectiveness was described using the Eczema Area and Severity Index (EASI), the Investigator’s Global Assessment (IGA), and the Itch and Sleep numerical rating scales (NRS) recorded as part of routine clinical practice. Persistence to treatment was estimated using Kaplan–Meier curves. Results Seventy-four patients were included and followed for a mean of 42.1 (standard deviation, SD 21.4) weeks. At baseline, over half of the patients had severe AD, with an EASI > 21 (63%) and an IGA-4 (56.8%). Patients had received a mean of 2.4 (SD 1.2) prior systemic treatments and were prescribed baricitinib mainly due to lack of effectiveness of previous treatment. Most patients were prescribed baricitinib as the sole systemic treatment for AD and did not receive any other systemic treatment during the follow-up. During the study period, 39.2% of patients discontinued baricitinib, mainly due to lack of effectiveness. At week 16, 69.7% of patients who remained on treatment and had a measurement available achieved a ≥ 75% improvement from baseline in the EASI (EASI75) response and 79.3% an IGA score of 0 or 1. Conclusions Among patients who remained on treatment, baricitinib showed meaningful clinical improvements in routine clinical practice in Spain. Our findings highlight rapid and sustained clinical improvements, aligning with that observed in other real-world studies. Infographic available for this article.

  • Open Access

    The diagnostic pathway of Alzheimer's disease in real-world clinical practice in Spain: results from the Adelphi Dementia Disease Specific Programme™

    by Pascual Sánchez-Juan, Pablo Baz, Enrique Arrieta, Diego Novick, Silvia Díaz-Cerezo, Sarah Cotton, Chloe Walker, Ángel Trueba Saiz, Mercedes Núñez

    Introduction: There are challenges associated with the timely diagnosis of people with mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially with the future introduction of amyloid-targeting therapies. This study evaluates the current diagnostic journey for MCI and dementia due to AD in Spain. Methods: This study used data from the Adelphi Real World Dementia Disease Specific Programme (DSP TM ), a cross-sectional survey with retrospective data collection. The survey involved primary care physicians (PCPs) and hospital specialists with experience in managing and treating AD, along with their consulting patients, between January and July 2023 in Spain. Analyses were descriptive. Results: Physicians ( N = 94; 44.7% PCPs, 38.3% neurologists) reported data for 723 patients. Most patients (78.9%) first consulted a PCP. The median (inter-quartile range) time since symptom onset to first consultation was 21.6 (6.1–48.2) weeks and, in those patients who were not diagnosed immediately, the time from first consultation to diagnosis was 13.0 (6.0–21.9) weeks if diagnosed by a PCP, or 28.9 (17.1–52.1) weeks if diagnosed by a specialist. The diagnosing physician was a specialist or a PCP for 83.2% and 16.8% of patients, respectively. In addition, the most used advanced diagnostic techniques were computed tomography scans and magnetic resonance imaging (57.2% and 43.3% of patients, respectively). CSF determination of AD biomarkers was conducted in 12.4% of patients and AD-specific blood biomarkers in 2.9%. Treatment was mostly initiated by neurologists. Conclusion: The diagnostic process for people with MCI and AD could be accelerated by increased awareness of the disease, shorter referral times, and better access to specialized diagnostic services. This study shows limited use of AD-specific biomarker testing in Spain.


  • Open Access

    A Systematic Literature Review of the Epidemiological, Diagnostic Workup, Humanistic, and Economic Burden of Alzheimer’s Disease in Spain

    by Miren Altuna, Eloy Rodríguez, Mercedes Núñez, Ángel Trueba-Saiz, Luis Lizan, Silvia Díaz-Cerezo

    Introduction: Alzheimer’s disease (AD), the leading cause of dementia, affects over 700,000 individuals in Spain, with prevalence expected to rise due to population aging and improved diagnostic accuracy. Around 40,000 new cases are diagnosed annually, yet early-stage AD dementia remains underdiagnosed, limiting understanding of its full epidemiological, clinical, humanistic, and economic burden in Spain. Methods: A systematic literature review (SLR) was conducted on the burden of AD dementia in Spain, focusing on observational studies published from January 2019 to January 2024. Searches were performed in PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE), Medicina en Español (MEDES), and Índice Bibliográfico Español en Ciencias de la Salud (IBECS), following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: Twenty-six publications were included, mainly addressing moderate-to-severe AD dementia, with limited evidence on mild cognitive impairment (MCI) due to AD. Commonly used tools included the Mini-Mental State Examination (MMSE), Barthel Index, and Global Deterioration Scale (GDS). Neurologists were the primary clinicians involved in diagnosis (78.6%), though etiological diagnosis often lacked core AD biomarkers. Most caregivers were informal (mainly women), experiencing significant declines in health-related quality of life (HRQoL). Non-healthcare costs accounted for 84.6%-90.7% of total expenditures, followed by direct healthcare (6.1%-10.0%) and social care costs (2.8%-4.6%). Indirect costs, mostly from reduced working hours, represented 0.5%-0.8%. Conclusions: This study highlights the need to improve early diagnosis of AD dementia and to establish reliable health registries to measure its burden. The lack of evidence on practice heterogeneity hinders standardized care strategies. Addressing these gaps is essential to improve patient management, ensure equitable access to timely and accurate diagnosis, and facilitate access to emerging disease-modifying treatments for AD dementia.


  • Open Access

    [Artículo traducido] Carga humanística y económica de la dermatitis atópica en los pacientes pediátricos en España: una revisión sistemática

    by A. Torrelo Fernández, A. Vicente, A. Martin-Santiago, R. de Lucas Laguna, J.C. Armario-Hita, R. Moro, S. Díaz-Cerezo, L. Lizán, M. Núñez

  • Open Access

    Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review

    by Patricia Pozo-Rosich, David García-Azorín, Silvia Díaz-Cerezo, Julia Fernández-Montoya, Héctor David de Paz, Mercedes Núñez

    Introduction: In the context of migraine preventive therapy, new therapeutic modalities such as monoclonal antibodies targeting the calcitonin gene-related peptide receptor (CGRP) or ligand offer potential advantages over traditional preventive treatments.Methods: This systematic literature review gathered recent real-world evidence from Spain on the use of galcanezumab, a CGRP-targeting treatment, in migraine patients. The review included observational studies in English or Spanish, published from August 2020 to August 2023, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Cochrane guidelines.Results: A total of 29 publications involving 2,592 Spanish adult patients were identified, reporting relevant information on clinical outcomes (treatment effectiveness and safety), treatment persistence and patterns (switching from other therapies and time to discontinuation and restart), and patient-reported outcomes (including satisfaction with treatment). The most frequently reported variables were related to the clinical effectiveness of galcanezumab, demonstrating a significant reduction in monthly migraine days and monthly headache days. Additionally, adverse impact of headache per HIT-6 (Headache Impact Test-6) and disability per MIDAS (Migraine Disability Assessment) also improve. Studies also showed that up to 12-month persistence to galcanezumab ranged from 76.8 to 59.8%. Serious adverse events were rare. None of the publications included health-related quality of life data, either generic or migraine-specific. One study highlighted that galcanezumab treatment would offer high patient satisfaction for people with migraine.Conclusion: The real-world evidence on the use of galcanezumab treatment among the Spanish population shows that its effectiveness, persistence, safety, and impact on health burden align with findings from clinical trials and observational studies conducted in other countries. Future studies should incorporate health-related quality of life data to gain a more holistic understanding of this treatment’s impact.


  • Open Access

    Humanistic and Economic Burden of Atopic Dermatitis in Pediatric Patients in Spain: A Systematic Review

    by A. Torrelo Fernández, A. Vicente, A. Martin-Santiago, R. de Lucas Laguna, J.C. Armario-Hita, R. Moro, S. Díaz-Cerezo, L. Lizán, M. Núñez


  • Open Access

    Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study

    by Samuel Díaz Insa, Ángel Guerrero, Javier Viguera, Vicente Medrano Martínez, Carlos Calle de Miguel, Jesús Porta-Etessam, Antonio Ciudad, Silvia Diaz-Cerezo, Ana Roncero Martín, Mercedes Núñez

    Introduction The efficacy of galcanezumab has been demonstrated in randomized controlled trials, but evidence about its use under clinical practice conditions is still limited. This study aimed to describe the characteristics of the patients treated with galcanezumab in routine clinical practice in Spain as well as treatment patterns, persistence, and effectiveness. Methods A retrospective chart review study was carried out in six hospitals. Information of adults with migraine, who started treatment with galcanezumab between November 2019 and September 2021, was analyzed until end or loss of follow-up. Continuous variables were described as mean (standard deviation, SD) and median (interquartile range, IQR), and categorical variables as frequency and percentages. Persistence to treatment was estimated using Kaplan–Meier analysis. Results A total of 314 patients were analyzed over median follow-up period of 17.5 months (13.8–20.7), with a mean age of 46.3 (12.6), 85% women, 80.6% chronic migraine, and reporting a mean of monthly migraine days of 16.7 (7.8). Overall, 72.9% had comorbid conditions, with anxiety and depression disorders being the most frequent. More than 60% had received ≥ 6 previous preventive drugs, the most common being antiepileptics, antidepressants, and botulinum toxin (95.2%, 89.8% and 84.1%, respectively). Overall, 60.3% of the patients with other preventive treatments maintained them after galcanezumab initiation. The median time on galcanezumab was 14.6 months (9.4–22.8); 95.7%, 82.0%, 76.2% and 59.8% of patients were persistent to treatment at 3, 6, 9 and 12 months, respectively. Of the patients who discontinued (151: 48.1%), 57.6% were due to lack of effectiveness and 31.1% were due to improvement in migraine. The average reduction of monthly migraine days at 3, 6, 9 and 12 months was 7.9 (7.2), 9.1 (7.5), 8.8 (6.6) and 9.0 (6.9) days, respectively. Conclusions In real clinical practice, galcanezumab is an effective treatment and has a high persistence in patients with migraine, mostly chronic and with multiple use of previous preventive treatments.


  • Open Access

    Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study

    by Beatriz Joven, Raquel Hernández Sánchez, Eva Pérez-Pampín, Ángel Aragón Díez, Raquel Almodóvar, Ángels Martínez-Ferrer, Joaquín Belzunegui, Esteban Rubio, Silvia Díaz-Cerezo, Sebastián Moyano, et al.

    Introduction Ixekizumab (IXE) is an IgG4-type monoclonal antibody targeting IL-17A indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients with insufficient response or with intolerance to one or more disease-modifying anti-rheumatic drug (DMARD) therapy. The PRO-STIP study aimed to describe persistence, patient characteristics, treatment patterns, and effectiveness in patients with PsA receiving IXE in a real-world clinical setting in Spain. Methods This was an observational, multicentric, retrospective, longitudinal study in adult PsA patients who started IXE between January 2019 and December 2020, with at least 24 weeks of follow-up. A descriptive analysis of patient characteristics and treatment patterns was performed. The primary objective, treatment persistence, was estimated by Kaplan–Meier survival curve. Effectiveness was evaluated by Disease Activity in Psoriatic Arthritis (DAPSA) scores at baseline and at 12 and 24 weeks. Results Eighty-nine patients met the selection criteria (55.1% women and mean age 51.5 years). The median time from PsA diagnosis to starting IXE was 7.7 years (IQR 3.4–14.6). Prior to IXE, 95.5% patients had been treated with at least one biologic or targeted synthetic DMARD (b/tsDMARD). The observed persistence rates were 95.5%, 84.3% and 68.5% at 24, 48, and 104 weeks, respectively. The median persistence was not reached in the study period (mean persistence, 86.9 [95% CI 80.6–93.2] weeks). Twenty-eight (31.5%) patients discontinued IXE, 19 patients (21.3%) due to loss of effectiveness and two patients (2.2%) due to adverse events. In patients receiving treatment and with available effectiveness assessment (n = 24), DAPSA decreased significantly from baseline 23.7 (95% CI 19.5–27.9) to 14.8 (95% CI 10.5–19.2) at 12 weeks (p = 0.005) and 14.3 (95% CI 11.1–17.4) at 24 weeks (p = 0.004). Conclusions PsA patients treated with IXE in a real-world setting show high treatment persistence through 104 weeks and improvements in disease activity after treatment initiation. This suggests that IXE could be an effective treatment for patients with PsA. Retrospectively registered Date of registration: 25th May 2021.


  • Open Access

    Burden and Unmet Needs in Migraine Patients: Results from the OVERCOME (Spain) Study

    by Julio Pascual, Mercedes Núñez, Tommaso Panni, Silvia Díaz-Cerezo, Diego Novick, Antonio Ciudad

    Introduction This analysis aimed to evaluate demographics, migraine-related disability, symptoms, diagnosis and healthcare consultation, work productivity, and treatment patterns according to headache frequency in adults with migraine in the OVERCOME (ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE) (Spain) study. Methods Data were obtained from an observational, cross-sectional, web-based survey conducted between October 2020–February 2021 in Spain. Eligible participants were adult members of online survey panels living in Spain who were able to read and write Spanish and fulfilled the International Classification of Headache Disorders, third edition (ICHD-3) criteria for migraine or had a self-reported physician diagnosis. Results In total, 10,229 patients comprised the Spanish sample. Only 56.2% of respondents had a confirmed healthcare professional (HCP) diagnosis of migraine, despite almost all meeting modified ICHD-3 criteria. Pain severity, migraine-related disability, and interictal burden increased with increasing number of headache days per month. Migraine impacted on respondents’ work productivity, with increases in presenteeism, work productivity loss, and daily activity impairment at higher headache frequencies. Over the past year, 66.2% of all HCP visits were specifically due to migraine, most commonly with a general practitioner or pharmacist. A subgroup of 1277 patients (12.5% of the total survey population) met eligibility criteria for migraine preventive medications, of whom only 36.6% were currently taking a preventive. Conclusions Results of the OVERCOME (Spain) survey reveal the substantial burden of migraine, which is directly linked to headache frequency. However, most patients experiencing frequent headaches and eligible for migraine preventives are currently not taking them. Findings highlight the importance of addressing unmet needs for people with migraine in Spain.


  • Open Access

    Adaptation and Validation of the Spanish Version of Decisional Conflict Scale in People with Migraine in Spain

    by Ángel Luis Guerrero-Peral, Jesús Porta-Etessam, Jaime Rodríguez-Vico, Mercedes Núñez, Antonio Ciudad, Silvia Díaz-Cerezo, Carla Garí-Peris, Francisco Javier Pérez-Sádaba, Luis Lizán, Sonia Santos-Lasaosa

    Purpose: We aimed to validate the Spanish version of the Decisional Conflict Scale (DCS) and analyze its psychometric properties in people with migraine. Patients and Methods: The DCS validation comprised two phases. First, a translation and cross-cultural adaptation following the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Good Practices: 1-preparation, 2-independent forward translation, 3-reconciliation, 4-back-translation, 5-harmonization, 6-clinical review, and 7-content validation in a group of migraine patients. Second, the analysis of the psychometric properties. The reliability or internal consistency of the DCS scale and subscales was assessed using Cronbach’s α value. The item-subscale correlation was also evaluated. A floor and ceiling effects for DCS score was considered when at least 15% of respondents obtained DCS > 90 (ceiling) or < 10 (floor). The construct validity was studied through the correlation between the DCS subscales and by the correlation between the DCS and other questionnaires (Decision Self-Efficacy Scale [DSES] and 9-item Shared Decision-Making [SDM-Q-9]). Spearman’s coefficients were estimated for the correlations. Results: The cross-cultural adaptation was conducted on 17 patients who completed the questionnaire in a mean of 2.4 ± 1.1 minutes. Generally, more than 75% of them considered that DCS items were adequate, easy to understand, and relevant. The psychometric properties were evaluated in a sample of n=128 patients. Accordingly, the internal consistency of DCS was high, with a Cronbach’s α of 0.97 for the scale and between 0.87 to 0.96 for subscales. Also, a slight floor effect was observed, with 24.2% of patients having DCS scores < 10. The correlation between subscales exceeded Spearman’s coefficient of 0.7. Whereas the correlation between the DCS and the other questionnaires was generally moderate (Spearman’s coefficient > 0.4). Conclusion: The Spanish version (Spain) of the DCS has very acceptable psychometric properties (reliability and construct validity) and good potential for assessing decisional conflicts among migraine patients.